That's a wrap.
Market opens Friday, Nov 13 at 9:30 AM ET
8:48 AMYahoo Finance
Zoetis' Cytopoint Plus gets USDA license for 75-Day Canine Itch relief
7:30 AMYahoo Finance
Zoetis Receives USDA license for Cytopoint Plus™: The first and only Long-Acting Monoclonal Antibody Providing 75 days of allergic itch relief in dogs with allergic dermatitis
5:52 AMYahoo Finance
What are Wall Street analysts' target price for Zoetis stock?
7:27 PMYahoo Finance
Should you buy Zoetis stock at this price?
Zoetis to participate in the Jefferies Global Healthcare Conference in London
4:41 AMYahoo Finance
ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
9:00 AMYahoo Finance
ZTS Q3 earnings call highlights competitive pressures and outlook
5:14 PMYahoo Finance
What Zoetis (ZTS) said on its Q3 earnings call
6:10 PMYahoo Finance
Zoetis (ZTS) stock price drops after Q3 earnings margin pressure
10:07 PMYahoo Finance
Zoetis: 3 key Takeaways for long-term investors
4:35 PMYahoo Finance
Zoetis (ZTS) Q3 2026 earnings call transcript
4:27 PMYahoo Finance
No Greyhounds here: Pet-Health Giant Zoetis Reverses 30% Monthlong Sprint
12:29 PMYahoo Finance
ZTS Q3 earnings top estimates, 2026 profit outlook Improves, stock up
8:30 AMYahoo Finance
Zoetis (ZTS) reports Q3 earnings: What key metrics have to Say
7:58 AMYahoo Finance
Zoetis (NYSE:ZTS) posts better-than-expected sales in Q3 2026
7:15 AMYahoo Finance
Zoetis (ZTS) Q3 earnings and revenues top estimates
7:10 AMYahoo Finance
Zoetis: Q3 earnings snapshot
7:00 AMYahoo Finance
Zoetis announces third quarter 2026 results; highlights Progress Advancing innovation across Diversified Portfolio and Narrows Full year 2026 revenue guidance, raises full year 2026 adjusted EPS guidance
5:10 PMYahoo Finance
Zoetis stock faces earnings test as US weakness weighs
6:57 AMYahoo Finance
6 big funds sold Zoetis. Should you Follow them before earnings?
9:15 AMYahoo Finance
Zoetis Gears up to report Q3 earnings: Here's what to expect
8:15 AMYahoo Finance
Insights into Zoetis (ZTS) Q3: Wall Street projections for key metrics